Jenscare Scientific Shows High Sucess Rate for Valve Replacement Systems During Separate Studies

MT Newswires Live

May 27, 2025

Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.

The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.

Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.

Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.

Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538637654"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538637654\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538637654?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538637654","market":"us","top_or_hot":-1,"title":"Jenscare Scientific Shows High Sucess Rate for Valve Replacement Systems During Separate Studies","media":"MT Newswires Live","content":"<html><body><p> Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.</p><p>The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.</p><p>Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.</p><p>Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.</p><p>Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jenscare Scientific Shows High Sucess Rate for Valve Replacement Systems During Separate Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJenscare Scientific Shows High Sucess Rate for Valve Replacement Systems During Separate Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-27 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.</p><p>The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.</p><p>Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.</p><p>Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.</p><p>Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2538637654","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538637654","pubTimestamp":1748345674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jenscare Scientific  said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","09877":"健世科技-B"},"translate_title":"Jenscare Scientific在单独的研究中显示瓣膜置换系统的高成功率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09877":0.9},"content_text":"Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}